secwatch.observer — SEC 8-K summary
======================================

Issuer:     SURMODICS INC (—)
CIK:        0000924717
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0000950170-24-050881
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surmodics Q2 revenue $32M (+18% YoY), GAAP net income $0.2M; raises FY2024 guidance; launches two thrombectomy devices
--------------------------------------------------------------------------------

- Total revenue $32.0M, up 18% YoY; GAAP net income $0.2M vs loss of $7.7M in prior-year period.
- Medical Device product sales up 40% to $11.1M, driven by SurVeil DCB commercial shipments and Pounce sales.
- Adjusted EBITDA $4.8M, improving from $(1.5M) in Q2 fiscal 2023.
- FY2024 guidance raised: revenue now $122-$124M; GAAP diluted loss per share $(0.90)-$(0.70) vs prior $(1.40)-$(1.10).
- Commercial launch of Pounce Venous and Pounce LP thrombectomy systems; cash and investments $40.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/924717/000095017024050881/0000950170-24-050881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/924717/000095017024050881/srdx-20240501.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-050881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer